The angiogenic switch in solid tumors: Clinical implications

Tumori

Volumn 1, Issue 6 SUPPL., 2002, Pages

  Tosetti, Francesca ^a   Benelli, Roberto ^a   Albini, Adriana ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOSTATIN; ANTIOXIDANT; BASIC FIBROBLAST GROWTH FACTOR; CYTOKINE; ENDOSTATIN; GLYCOLYTIC ENZYME; HYPOXIA INDUCIBLE FACTOR 1; INTERFERON; INTERLEUKIN 12; METALLOPROTEINASE; MITOGENIC AGENT; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDE DERIVATIVE; PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SU 668; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ACTIVITY; HUMAN; HYPOXEMIA; SOLID TUMOR; TUMOR VASCULARIZATION;

EID: 0036836907     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/03008916020016s103     Document Type: Conference Paper

References (20)

1. Ellis L, Liu W, Ahmad S, Fan F, Jung Y, Shaheen R, Reinmuth N: Overview of angiogenesis: biologic implications for antiangiogenic therapy. Semin Oncol, 28: 94-104, 2001.
2. Bergers G, Brekken R, McMahon G, Vu T, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol, 2: 737-744, 2000.
3. Siemeister G, Schirner M, Weindel K, Reusch P, Menrad A, Marme D, Martiny-Baron G: Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. Cancer Res, 59: 3185-3191, 1999.
4. Graeven U, Rodeck U, Karpinski S, Jost M, Philippou S, Schmiegel W: Modulation of angiogenesis and tumorigenicity of human melanocytic cells by vascular endothelial growth factor and basic fibroblast growth factor. Cancer Res, 61: 7282-7290, 2001.
5. Hawighorst T, Skobe M, Streit M, Hong Y, Velasco P, Brown L, Riccardi L, Lange-Asschenfeldt B, Detmar M: Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am J Pathol, 160: 1381-1392, 2002.
6. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.
7. Lippman SM, Matrisian LM: Protease inhibitors in oral carcinogenesis and chemoprevention. Clin Cancer Res, 6, 4599-4603, 2000.
8. Herbst R, Hidalgo M, Pierson A, Holden S, Bergen M, Eckhardt S: Angiogenesis inhibitors in clinical development for lung cancer. Semin Oncol, 29: 66-77, 2002.
9. Semenza G: HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev, 19: 59-65, 2000.
10. Fang J, Yan L, Shing Y, Moses M: HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. Cancer Res, 61: 5731-5735, 2001.
11. Wedge S, Ogilvie D, Dukes M, Kendrew J, Curwen J, Hennequin L, Thomas A, Stokes E, Curry B, Richmond GH, Wadsworth PF: ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res, 60: 970-975, 2000.
12. Hartman G, Fraley M, Bilodeau M: Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents. Expert Opin Investig Drugs, 11: 737-745, 2002.
13. Arbiser J, Petros J, Klafter R, Govindajaran B, McLaughlin E, Brown L, Cohen C, Moses M, Kilroy S, Arnold R, Lambeth J: Reactive oxygen generated by Noxl triggers the angiogenic switch. Proc Natl Acad Sci USA, 99: 715-720, 2002.
14. Tosetti F, Ferrari N, De Flora S, Albini A: Angioprevention: angiogenesis is a common and key target for cancer chemo-preventive agents. FASEB J, 16: 2-14, 2002.
15. Decensi A, Bonanni B, Guerrieri-Gonzaga A, Torrisi R, Manetti L, Robertson C, De Palo G, Formelli F, Costa A, Veronesi U: Chemoprevention of breast cancer: the Italian experience. J Cell Biochem Suppl, 34: 84-96, 2000.
16. Folkman J: Angiogenesis-dependent diseases. Semin Oncol, 28: 536-542, 2001.
17. Zhang L, Yu D, Hicklin D, Hannay J, Ellis L, Pollock R: Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. Cancer Res, 62: 2034-2042, 2002.
18. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett N, Crystal R, Moore M, Hajjar K, Manova K, Benezra R, Rafii S: Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med, 7: 1194-1201, 2001.
19. Benelli R, Morini M, Carrozzino F, Ferrari N, Minghelli S, Santi L, Cassatella M, Noonan DM, Albini A: Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. Faseb J, 16: 267-269, 2002.
20. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, Hanahan D: Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev, 13: 1382-1397, 1999.